CATURANO, ALFREDO
 Distribuzione geografica
Continente #
EU - Europa 1.962
AS - Asia 1.847
NA - Nord America 1.123
SA - Sud America 323
AF - Africa 18
OC - Oceania 2
Totale 5.275
Nazione #
RU - Federazione Russa 1.160
US - Stati Uniti d'America 1.087
SG - Singapore 631
CN - Cina 472
HK - Hong Kong 301
BR - Brasile 261
IT - Italia 255
IE - Irlanda 242
VN - Vietnam 122
KR - Corea 120
DE - Germania 97
IN - India 85
GB - Regno Unito 59
JP - Giappone 31
FR - Francia 26
AR - Argentina 24
MX - Messico 18
ID - Indonesia 15
SE - Svezia 15
FI - Finlandia 13
CA - Canada 12
PL - Polonia 12
AT - Austria 11
NL - Olanda 11
ES - Italia 10
TR - Turchia 10
EC - Ecuador 9
CO - Colombia 8
VE - Venezuela 8
CZ - Repubblica Ceca 7
LT - Lituania 7
PK - Pakistan 7
AE - Emirati Arabi Uniti 6
BE - Belgio 6
GR - Grecia 6
IL - Israele 6
IR - Iran 6
UA - Ucraina 6
BD - Bangladesh 5
EG - Egitto 5
MA - Marocco 5
PE - Perù 5
ZA - Sudafrica 5
CH - Svizzera 3
IQ - Iraq 3
JO - Giordania 3
KG - Kirghizistan 3
LB - Libano 3
UY - Uruguay 3
AU - Australia 2
AZ - Azerbaigian 2
BA - Bosnia-Erzegovina 2
BO - Bolivia 2
CL - Cile 2
DK - Danimarca 2
LA - Repubblica Popolare Democratica del Laos 2
MO - Macao, regione amministrativa speciale della Cina 2
PT - Portogallo 2
RO - Romania 2
RS - Serbia 2
TT - Trinidad e Tobago 2
UZ - Uzbekistan 2
AL - Albania 1
AM - Armenia 1
BB - Barbados 1
BG - Bulgaria 1
CI - Costa d'Avorio 1
DM - Dominica 1
DO - Repubblica Dominicana 1
DZ - Algeria 1
EE - Estonia 1
GE - Georgia 1
JM - Giamaica 1
KW - Kuwait 1
LV - Lettonia 1
MD - Moldavia 1
NO - Norvegia 1
NP - Nepal 1
PS - Palestinian Territory 1
PY - Paraguay 1
QA - Qatar 1
SA - Arabia Saudita 1
SY - Repubblica araba siriana 1
TJ - Tagikistan 1
TN - Tunisia 1
TW - Taiwan 1
Totale 5.275
Città #
Moscow 409
Singapore 304
Hong Kong 299
Dublin 228
Santa Clara 195
Hefei 144
Chandler 132
Seoul 119
The Dalles 115
Naples 80
Bengaluru 67
New York 64
Ashburn 55
Ho Chi Minh City 44
Munich 42
Beijing 41
Dallas 38
São Paulo 27
Princeton 22
Roxbury 22
Cambridge 20
Hanoi 19
Los Angeles 19
Falkenstein 15
Bremen 13
Salerno 12
Belo Horizonte 10
Stockholm 10
Amsterdam 9
Atlanta 9
Boston 9
Brooklyn 9
Da Nang 9
Milan 9
Caserta 8
Frankfurt am Main 8
Des Moines 7
Ercolano 7
Helsinki 7
Istanbul 7
Liveri 7
Mexico City 7
Nuremberg 7
Bexley 6
Brussels 6
Chennai 6
Florence 6
Guarulhos 6
Houston 6
Lahore 6
Napoli 6
Boardman 5
Changsha 5
Curitiba 5
Denver 5
Jacksonville 5
Nanjing 5
Rio de Janeiro 5
Tokyo 5
Warsaw 5
Brno 4
Bắc Ninh 4
Chicago 4
Damietta 4
Duncan 4
Haiphong 4
Hải Dương 4
Lappeenranta 4
London 4
Manchester 4
Nonantola 4
Paris 4
Quito 4
Rome 4
San Francisco 4
Shenzhen 4
Tel Aviv 4
Tianjin 4
Toronto 4
Vienna 4
Wroclaw 4
Amman 3
Andover 3
Beaverton 3
Bogotá 3
Boydton 3
Can Tho 3
Casablanca 3
Chengdu 3
Columbus 3
Dhaka 3
Eboli 3
Florianópolis 3
Goiânia 3
Guangzhou 3
Guayaquil 3
Johannesburg 3
Lima 3
Maceió 3
Medford 3
Totale 2.918
Nome #
ULTRASOUND TIPS IN THE LUNG CANCER DIAGNOSIS: A PILOT STUDY 110
Association between Renal Function at Admission and COVID-19 in-Hospital Mortality in Southern Italy: Findings from the Prospective Multicenter Italian COVOCA Study 108
Aspirin in a Diabetic Retinopathy Setting: insights from NO BLIND Study 104
Cardiac Hypertrophy: from Pathophysiological Mechanisms to Heart Failure Development 104
Can Metformin Exert as an Active Drug on Endothelial Dysfunction in Diabetic Subjects? 95
Cardiorenal Impact of SGLT-2 Inhibitors: A Conceptual Revolution in The Management of Type 2 Diabetes, Heart Failure and Chronic Kidney Disease 95
null 93
Cardiovascular benefits from gliflozins: Effects on endothelial function 91
Effects of a Combination of Empagliflozin Plus Metformin vs. Metformin Monotherapy on NAFLD Progression in Type 2 Diabetes: The IMAGIN Pilot Study 88
Comment on: Effect of Vitamin D supplementation in patients with liver cirrhosis having spontaneous bacterial peritonitis: a randomized controlled study 87
Dysregulated Epicardial Adipose Tissue as a Risk Factor and Potential Therapeutic Target of Heart Failure with Preserved Ejection Fraction in Diabetes 86
HCC and molecular targeting therapies: Back to the future 85
Current Knowledge on the Pathophysiology of Lean/Normal-Weight Type 2 Diabetes 84
Peripheral Neuropathy in Diabetes Mellitus: Pathogenetic Mechanisms and Diagnostic Options 84
Impact of direct acting antivirals (DAAs) on cardiovascular events in HCV cohort with pre-diabetes 83
Coronary Microvascular Dysfunction in Diabetes Mellitus: Pathogenetic Mechanisms and Potential Therapeutic Options 81
Left bundle branch pacing and cardiac remodeling in HF patients with type 2 diabetes mellitus: epigenetic pathways and clinical outcomes 79
Impact of gliflozins on cardiac remodeling in patients with type 2 diabetes mellitus & reduced ejection fraction heart failure: A pilot prospective study. GLISCAR study 77
The Importance of Telemedicine during COVID-19 Pandemic: A Focus on Diabetic Retinopathy 76
Comment on: Warfarin adherence and anticoagulation control in atrial fibrillation patients-a systematic review 76
Lack of effect on in-hospital mortality of drugs used during COVID-19 pandemic: Findings of the retrospective multicenter COVOCA study 74
Liver Involvement in Patients With Systemic Sclerosis: Role of Transient Elastography in the Assessment of Hepatic Fibrosis and Steatosis 73
Impact of chronic liver disease upon admission on COVID-19 in-hospital mortality: Findings from COVOCA study 73
The number of risk factors not at target is associated with cardiovascular risk in a type 2 diabetic population with albuminuria in primary cardiovascular prevention. Post-hoc analysis of the NID-2 trial 71
Anti-Inflammatory and Anticancer Effects of Anticoagulant Therapy in Patients with Malignancy 71
Pathophysiological mechanisms and clinical evidence of relationship between Nonalcoholic fatty liver disease (NAFLD) and cardiovascular disease 71
CURRENT HEPATOCELLULAR CARCINOMA SYSTEMIC PHARMACOLOGICAL TREATMENT OPTIONS 70
An Update on Betrixaban, the Challenging Anticoagulant Agent for Extended Venous Thromboembolism Prophylaxis 69
Impact of Acute Kidney Injury on the COVID-19 In-Hospital Mortality in Octogenarian Patients: Insights from the COVOCA Study 68
Diabetic Gastroparesis: Navigating Pathophysiology and Nutritional Interventions 68
Polypharmacy and major adverse events in atrial fibrillation 67
Effects of metformin in heart failure: From pathophysiological rationale to clinical evidence 67
Non-alcoholic Fatty Liver Disease (NAFLD), Type 2 Diabetes, and Non-viral Hepatocarcinoma: Pathophysiological Mechanisms and New Therapeutic Strategies 66
The prognostic role of interatrial block among COVID-19 patients hospitalized in medicine wards 66
Optimizing Anticoagulation Management in Atrial Fibrillation: Beyond the Guidelines. How and for Whom? 65
Efficacy and durability of multifactorial intervention on mortality and MACEs: a randomized clinical trial in type-2 diabetic kidney disease 65
Oxidative Stress in Type 2 Diabetes: Impacts from Pathogenesis to Lifestyle Modifications 65
EFFICACY OF COVID-19 VACCINATION IN PATIENTS WITH IMMUNE SYSTEM DISORDERS AND CANCER 64
Sex-difference of multifactorial intervention on cardiovascular and mortality risk in DKD: post-hoc analysis of a randomised clinical trial 63
The Lipid-Lowering Efficacy of a Nutraceutical Combination Including Leucoselect Phytosome, Red Yeast Rice, Policosanol and Folic Acid in Dyslipidaemia Patients: Real-World Insights 63
Non-Alcoholic Fatty Liver Disease: From Pathogenesis to Clinical Impact 63
Mechanisms of non-alcoholic fatty liver disease in the metabolic syndrome. A narrative review 63
Brugada syndrome and COVID-19 vaccines 62
Effects of Heart Failure Therapies on Atrial Fibrillation: Biological and Clinical Perspectives 61
The Diabetic Cardiomyopathy: The Contributing Pathophysiological Mechanisms 61
ULTRASOUND TIPS IN THE LUNG CANCER DIAGNOSIS: A PILOT STUDY 60
The Significance of Statin-Associated Muscle Symptoms and Its Impact on Patient Adherence and Outcomes 59
Long-term clinical outcomes of patients with drug-induced type 1 Brugada electrocardiographic pattern: A nationwide cohort registry study 58
Role of Albuminuria in Detecting Cardio-Renal Risk and Outcome in Diabetic Subjects 58
Modern Challenges in Type 2 Diabetes: Balancing New Medications with Multifactorial Care 57
Effects of Metformin in Heart Failure: From Pathophysiological Rationale to Clinical Evidence 57
Cardiovascular Benefits from Gliflozins: Effects on Endothelial Function 56
Assessment of the Effectiveness of Ticagrelor Preloading in Mitigating Periprocedural Myocardial Injury Among Non-ST Elevation Myocardial Infarction Patients Opting for an Early Invasive Approach 56
Predictive Value of Fatty Liver Index for Long-Term Cardiovascular Events in Patients Receiving Liver Transplantation: The COLT Study 56
The Role of Neuropathy Screening Tools in Patients Affected by Fibromyalgia 56
Insulin–Heart Axis: Bridging Physiology to Insulin Resistance 55
High HDL Cholesterol: a risk factor for Diabetic Retinopathy? Findings from NO BLIND study 55
Impact of liver fibrosis on COVID-19 in-hospital mortality in Southern Italy 55
Antioxidant and Antidiabetic Potential of the Antarctic Lichen Gondwania regalis Ethanolic Extract: Metabolomic Profile and In Vitro and In Silico Evaluation 54
Alcohol Consumption and Liver Metabolism in the Era of MASLD: Integrating Nutritional and Pathophysiological Insights 54
Late Hepatocellular Carcinoma Occurrence in Patients Achieving Sustained Virological Response After Direct-Acting Antiviral Therapy: A Matter of Follow-Up or Something Else? 54
The impact of new onset diabetes on cardiovascular risks in orthotopic liver transplant recipients: findings from the COLT study 51
Insulin resistance and cancer: molecular links and clinical perspectives 50
NerveCheck master to screen patients with type 1 or type 2 diabetes for peripheral and cardiac autonomic neuropathy 50
Commentary on Antithrombotic Effect of Protopanaxatriol Saponins from Panax notoginseng Using Zebrafish Model 50
Right ventricular electrocardiographic abnormalities among hospitalized COVID-19 patients: Simple marker of worst clinical outcome 49
Clinical Utilization and Performance of Bempedoic Acid in an Italian Real-World Setting: Insight from Campania Region 49
Pharmacogenomics of Cardiovascular Drugs for Atherothrombotic, Thromboembolic and Atherosclerotic Risk 46
Multidrug-Resistant Infections and Metabolic Syndrome: An Overlooked Bidirectional Relationship 45
The Diabetic Cardiomyopathy: The Contributing Pathophysiological Mechanisms 44
Sodium-Glucose Cotransporter 2 Inhibitors in Patients with Diabetes and Coronary Artery Disease: Translating the Benefits of the Molecular Mechanisms of Gliflozins into Clinical Practice 44
Assessment of Response and Safety of Bulevirtide Treatment in Patients with Chronic Delta Virus Infection: The ARISTOTLE Pilot Observational Study 44
Predictors of Plasma Levels of Direct Oral Anticoagulants Among Patients with Atrial Fibrillation in Need of Elective Cardiac Procedures 43
Serum Lipids, Inflammation, and the Risk of Atrial Fibrillation: Pathophysiological Links and Clinical Evidence 43
Clinical performance of subcutaneous vs. transvenous implantable defibrillator in patients with ischemic cardiomyopathy: data from Monaldi Rhythm Registry 43
Metabolic Rewiring of Bacterial Pathogens in Response to Antibiotic Pressure—A Molecular Perspective 41
Precision Medicine in Type 2 Diabetes Mellitus: Utility and Limitations 39
Remdesivir treatment and clinical outcome in non-severe hospitalized COVID-19 patients: a propensity score matching multicenter Italian hospital experience 38
The Intestinal Thread of Fate: How the Microbiota Shapes the Story of Liver Disease 35
Impact of Gliflozins on Right Heart Remodeling in Italian Patients with Type 2 Diabetes and Heart Failure: Results from the GLISCAR Real-World Study 33
Editorial on: Canagliflozin Mediates Mitophagy Through the AMPK/PINK1/PARKIN Pathway to Alleviate Isoprenaline-Induced Cardiac Remodeling 31
Oral Anticoagulation for Atrial Fibrillation in Octogenarians Across the Renal Function Spectrum 30
The transition from NAFLD to MASLD: implications for Diagnosis, Prognosis, and Clinical Management 28
Impact of SGLT2 Inhibitors on Heart Failure: From Pathophysiology to Clinical Effects 26
When the dual-chamber pacing system is the optimal choice for Brugada patients in need of implantable cardiac defibrillator 25
Metabolic dysfunction‐associated steatotic liver disease, insulin resistance and hepatocellular carcinoma: A deadly triad 24
Metabolic Dysfunction-Associated Steatotic Liver Disease in Klinefelter Syndrome: High Prevalence Uncovers an Unmet Need 22
Does a strict glycemic control during acute coronary syndrome play a cardioprotective effect? Pathophysiology and clinical evidence 20
Totale 5.398
Categoria #
all - tutte 21.997
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 21.997


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202128 0 0 0 0 0 4 6 4 3 3 5 3
2021/2022197 11 1 8 19 33 8 4 4 11 16 29 53
2022/2023498 28 28 15 19 67 30 5 31 230 11 10 24
2023/2024363 34 17 13 25 77 63 9 9 8 28 30 50
2024/20251.371 13 17 5 26 209 146 215 125 195 120 120 180
2025/20262.924 377 443 384 305 637 778 0 0 0 0 0 0
Totale 5.398